We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Two Years After Winning Accelerated Approval, GSK Pulls Blenrep At FDA’s Request
Two Years After Winning Accelerated Approval, GSK Pulls Blenrep At FDA’s Request
Two years after its blood cancer treatment Blenrep (belantamab mafodotin) won accelerated approval from the FDA, GSK has removed the drug from the market in the U.S. at the FDA’s request.